{
      "Rank": 237,
      "Acronym": [
            "MSC"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group I disease 0-7. days,",
            "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group II; 8-14 days of the disease. days",
            "In mesenchymal stem cell application, according to the diagnosis of COVID 19 and the day of stem cell application; Group III; It will be divided into 3 groups as those applied on the 15th day and after."
      ],
      "ArmGroupInterventionName": [
            "Drug: Mesenchymal Stem Cell Antigen-1, Human",
            "Drug: Mesenchymal Stem Cell Antigen-1, Human",
            "Drug: Mesenchymal Stem Cell Antigen-1, Human"
      ],
      "ArmGroupLabel": [
            "stem cell application; Group I disease 0-7. days,",
            "stem cell application; Group II; 8-14 days of the disease. days",
            "stem cell application; Group III; those applied on the 15th day and after."
      ],
      "ArmGroupType": [],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT05240430"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Mesenchymal stem cell (MSC) therapy is among the promising treatments for acute respiratory distress syndrome (ARDS). Our study aimed to investigate the clinical efficacy of MSC treatment in COVID-19 patients, to determine when this treatment can be applied to which patient, and to evaluate its contribution to prognosis."
      ],
      "BriefTitle": [
            "When to Apply to Which Patient in MSC?"
      ],
      "CentralContactEMail": [
            "erinrecep@gmail.com",
            "drseyfikartal@gmail.com"
      ],
      "CentralContactName": [
            "Recep ER\u0130N, MD",
            "Seyfi KARTAL, MD"
      ],
      "CentralContactPhone": [
            "+90462 341 5656",
            "+904623415656"
      ],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "March 31, 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "COVID-19 Acute Respiratory Distress Syndrome"
      ],
      "ConditionAncestorId": [
            "D000012141",
            "D000007239",
            "D000011024",
            "D000011014",
            "D000014777",
            "D000018352",
            "D000003333",
            "D000030341",
            "D000012327",
            "D000008171",
            "D000012140",
            "D000012120",
            "D000007235",
            "D000007232",
            "D000055370"
      ],
      "ConditionAncestorTerm": [
            "Respiratory Tract Infections",
            "Infections",
            "Pneumonia, Viral",
            "Pneumonia",
            "Virus Diseases",
            "Coronavirus Infections",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Lung Injury"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC01",
            "BC08",
            "All",
            "BC23",
            "BC16",
            "BC26",
            "BXS",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Infections",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "All Conditions",
            "Symptoms and General Pathology",
            "Diseases and Abnormalities at or Before Birth",
            "Wounds and Injuries",
            "Urinary Tract, Sexual Organs, and Pregnancy Conditions",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "COVID-19",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome",
            "Acute Respiratory Distress Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M2562",
            "M15507",
            "M14117",
            "M14116",
            "M27297",
            "M27296",
            "M9435",
            "M14130",
            "M5520",
            "M13056",
            "M13066",
            "M16674",
            "M19643",
            "M5707",
            "M22838",
            "M14301",
            "M10320",
            "M14129",
            "M14109",
            "M25022",
            "M9431",
            "M9428",
            "T4927",
            "T192",
            "T170"
      ],
      "ConditionBrowseLeafName": [
            "COVID-19",
            "Syndrome",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury",
            "Lung Injury",
            "Infections",
            "Respiratory Tract Infections",
            "Communicable Diseases",
            "Pneumonia",
            "Pneumonia, Viral",
            "Virus Diseases",
            "Coronavirus Infections",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases",
            "Respiration Disorders",
            "Premature Birth",
            "Infant, Premature, Diseases",
            "Infant, Newborn, Diseases",
            "Respiratory Distress Syndrome, Infant",
            "Acute Respiratory Distress Syndrome",
            "Acute Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "low",
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high",
            "high",
            "low"
      ],
      "ConditionMeshId": [
            "D000086382",
            "D000012128",
            "D000012127",
            "D000055371"
      ],
      "ConditionMeshTerm": [
            "COVID-19",
            "Respiratory Distress Syndrome",
            "Respiratory Distress Syndrome, Newborn",
            "Acute Lung Injury"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [],
      "DesignInterventionModel": [],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [
            "Case-Only"
      ],
      "DesignPrimaryPurpose": [],
      "DesignTimePerspective": [
            "Other"
      ],
      "DesignWhoMasked": [],
      "DetailedDescription": [
            "The study was conducted retrospectively in patients diagnosis of COVID-19 in the intensive care units. Patients with severe ARDS [partial pressure of arterial blood oxygen and inhaled oxygen fraction (PaO2: FiO2) ratio of 100 or less] were included in the study. Demographic data of the patients (gender, age), comorbidities (hypertension, coronary heart disease, diabetes, cerebrovascular diseases, hepatitis B infection, cancer, chronic kidney disease, and immunodeficiency), Charlson comorbidity index (CMI), date of diagnosis, date of admission to the hospital, date of admission to the ICU, Acute Physiology And Chronic Health Evaluation (APACHE) II score, presence of high flow nasal oxygen (HFNO) or mechanical ventilator (MV) support, laboratory findings (blood cell count, blood biochemistry, hepatorenal function, coagulation function, D-dimer, C-reactive protein (CRP), procalcitonin, ferritin, arterial blood gas analysis) before (day 0) and after MSC application, on 3rd and 7th days, partial oxygen/fractionated oxygen (Pa/Fi) ratio, discharge or death information, and attributed causes of death were recorded on the study form. Pa/Fi ratio was calculated with the formula (oxygen dissolved in arterial blood gas / oxygen liter given to the patient)."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients who were followed up and treated after being admitted to the Intensive Care Unit after March 2020\nPatients with COVID PCR +\nTypical or suspected cases of Thorax BT COVID\nCases over the age of 18.\n\nExclusion Criteria:\n\nThose with a contraindicated condition (cancer disease, allergy) for MSC application\nThose who are endotracheal intubated during the application and are connected to a respirator\nThose who died in the first 24 hours after the application\nCases that are not positive or suspicious for COVID.\nCases under the age of 18.\nCases where patient data could not be reached."
      ],
      "EnrollmentCount": [
            "1"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [
            "No personal data belonging to the participants were used."
      ],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "stem cell application; Group I disease 0-7. days,",
            "stem cell application; Group II; 8-14 days of the disease. days",
            "stem cell application; Group III; those applied on the 15th day and after."
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Human umbilical cord-derived MSCs were used in the study. MSCs were prepared/obtained/produced/provided by Atigen-Cell Technology Center, Trabzon, Turkey. MSC for patients was calculated as a single dose, 1x106 cells per kilogram. MSC was infused in 100 ml of normal saline at 2 ml/min over 40 min, as described in previous studies"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal Stem Cell Antigen-1, Human"
      ],
      "InterventionOtherName": [
            "Human umblical cord deriveted Mesenchymal Stem Cell"
      ],
      "InterventionType": [
            "Drug"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [
            "No"
      ],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "COVID-19",
            "SARS-CoV-2",
            "Mesenchymal Stem Cell",
            "Intensive Care Units"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "February 15, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "February 13, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Trabzon Kanuni Education and Research Hospital"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Trabzon"
      ],
      "LocationContactEMail": [
            "drseyfikartal@gmail.com"
      ],
      "LocationContactName": [
            "Seyfi KARTAL, MD",
            "Esra Kongur, MD",
            "Z\u00fcbeyir Sivrikaya, MD",
            "G\u00fcrdal Y\u0131lmaz, MD"
      ],
      "LocationContactPhone": [
            "+90462 341 5656"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Sub-Investigator",
            "Sub-Investigator",
            "Sub-Investigator"
      ],
      "LocationCountry": [
            "Turkey"
      ],
      "LocationFacility": [
            "Trabzon Kanuni Training and Research Hospital, University of Healthy Sciences"
      ],
      "LocationState": [
            "Yomra"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "61500"
      ],
      "MaximumAge": [],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Effectiveness of Mesenchymal Stem Cell in Patients With COVID-19 Associated SARS-CoV-2, Retrospective Clinical Study: When to Apply to Which Patient?"
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Trabzon Kanuni Education and Research Hospital"
      ],
      "OrgStudyId": [
            "Trabzon Kanuni TRH"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Trabzon Kanuni Training and Research Hospital, University of Healthy Sciences, Trabzon, Turkey"
      ],
      "OverallOfficialName": [
            "Ahmet AKYOL, MD"
      ],
      "OverallOfficialRole": [
            "Study Chair"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [
            "Yes"
      ],
      "Phase": [],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "February 28, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "It was aimed to observe the changes in C-reactive protein (CRP), after MSC administration at different times (groups 1,2,3).",
            "It was aimed to observe the changes in procalcitonin after MSC administration at different times (groups 1,2,3).",
            "It was aimed to observe the changes in white blood cell count after MSC administration at different times (groups 1,2,3).",
            "It was aimed to observe the changes in respiratory support (such as high-flow nasal oxygen, mask with reservoir, and mechanical ventilation) after MSC administration at different times (groups 1,2,3).",
            "It was aimed to observe the changes in arterial blood gas analysis after MSC administration in Groups I, II, III."
      ],
      "PrimaryOutcomeMeasure": [
            "Change in acute phase reactants (C-reactive protein (CRP) after MSC administration in group I, II, III",
            "Change in acute phase reactants (procalcitonin) after MSC administration in group I, II, III",
            "Change in acute phase reactants ( white blood cell count) after MSC administration in group I, II, III",
            "Changes in respiratory support after MSC administration in Groups I, II, III",
            "Changes in arterial blood gas analysis (partial oxygen/fractionated oxygen (Pa/Fi) ratio) after MSC administration in Groups I, II, III"
      ],
      "PrimaryOutcomeTimeFrame": [
            "MSC treatment Group I disease 0-7. days, Group II; 8-14 days of the disease. days, Group III; Those applied on the 15th day and after",
            "MSC treatment Group I disease 0-7. days, Group II; 8-14 days of the disease. days, Group III; Those applied on the 15th day and after",
            "MSC treatment Group I disease 0-7. days, Group II; 8-14 days of the disease. days, Group III; Those applied on the 15th day and after",
            "MSC treatment Group I disease 0-7. days, Group II; 8-14 days of the disease. days, Group III; Those applied on the 15th day and after",
            "MSC treatment before (day 0) and after MSC application, on 3rd and 7th days,"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Trabzon Kanuni Education and Research Hospital"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Seyfi KARTAL, MD"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Assistant professor"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [
            "Non-Probability Sample"
      ],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "The effect of MSC application at different times on mortality will be evaluated."
      ],
      "SecondaryOutcomeMeasure": [
            "Effect on mortality after MSC administration in Groups I, II, III"
      ],
      "SecondaryOutcomeTimeFrame": [
            "7, 14 and 28 days after MSC application"
      ],
      "SeeAlsoLinkLabel": [
            "Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series",
            "Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells"
      ],
      "SeeAlsoLinkURL": [
            "https://pubmed.ncbi.nlm.nih.gov/33514427/",
            "https://pubmed.ncbi.nlm.nih.gov/32811531/"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "January 1, 2022"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "February 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "February 15, 2022"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "January 27, 2022"
      ],
      "StudyFirstSubmitQCDate": [
            "February 13, 2022"
      ],
      "StudyPopulation": [
            "COVID PCR positive\n\nThose who received MSC treatment\nThose with advanced respiratory failure\nThose who have progressed despite the standard recommended (antiviral, steroid, anticoagulant and vitamin) supportive treatment"
      ],
      "StudyType": [
            "Observational"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [
            "4 Weeks"
      ],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}